Clinical Trial Update: Open-label Long-term Safety Study of AT1001 (Migalastat Hydrochloride) in Participants With Fabry Disease Who Have Completed a Previous AT1001 Study [Phase 2]

View source ↗

Summary

Open-label long-term safety study of migalastat hydrochloride (AT1001) in Fabry disease participants who completed a prior AT1001 study; terminated with results…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fabry Disease

Drugs mentioned

• Migalastat hydrochloride (migalastat hydrochloride)

Snippet

Sponsor: Amicus Therapeutics | Conditions: Fabry Disease | Phase 2 | Status: TERMINATED | Results posted: 2018-10-03